Clinical Trials · NCT02811809
Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Withdrawn
- Sponsor
- The University of Texas Health Science Center, Houston
- Enrollment
- 0
- Start date
- Dec 2020
- Locations
- 1 site, United States
- Primary endpoint
- Time to second injection